BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 28.12.2020

Interim Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act; Public Meeting; Request for Comments

The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public meeting entitled "Interim Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act (BsUFA)" and an opportunity for public comment. The topics to be discussed are the interim assessment and public stakeholder views of the program to date.

Source: Federal Register — Food and Drug AdministrationOpen original release →